Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Condition aggravated, Headache, Rash, Vaccination site erythema, Vaccination site pain
Clinical narrative: headaches since the first vaccine; warmth/redness, warmth, itching and soreness on the injection site; rash that has been increasing in size/the rash is now the sized of her open hand; rash that has been increasing in size; itching/redness, warmth, itching and soreness on the injection site; redness, warmth, itching and soreness on the injection site; redness, warmth, itching and soreness on the injection site; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 04-Mar-2021 and was forwarded to Moderna on 04-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (warmth/redness, warmth, itching and soreness on the injection site), CONDITION AGGRAVATED (rash that has been increasing in size/the rash is now the sized of her open hand), RASH (rash that has been increasing in size), VACCINATION SITE PRURITUS (itching/redness, warmth, itching and soreness on the injection site) and VACCINATION SITE ERYTHEMA (redness, warmth, itching and soreness on the injection site) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was reported.  Concomitant products included METFORMIN, LISINOPRIL and ATENOLOL for an unknown indication.    On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Feb-2021, the patient experienced VACCINATION SITE WARMTH (warmth/redness, warmth, itching and soreness on the injection site), CONDITION AGGRAVATED (rash that has been increasing in size/the rash is now the sized of her open hand), RASH (rash that has been increasing in size), VACCINATION SITE PRURITUS (itching/redness, warmth, itching and soreness on the injection site), VACCINATION SITE ERYTHEMA (redness, warmth, itching and soreness on the injection site) and VACCINATION SITE PAIN (redness, warmth, itching and soreness on the injection site). On an unknown date, the patient experienced HEADACHE (headaches since the first vaccine). At the time of the report, VACCINATION SITE WARMTH (warmth/redness, warmth, itching and soreness on the injection site), CONDITION AGGRAVATED (rash that has been increasing in size/the rash is now the sized of her open hand), RASH (rash that has been increasing in size), VACCINATION SITE PRURITUS (itching/redness, warmth, itching and soreness on the injection site), VACCINATION SITE ERYTHEMA (redness, warmth, itching and soreness on the injection site), VACCINATION SITE PAIN (redness, warmth, itching and soreness on the injection site) and HEADACHE (headaches since the first vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details were not provided.   This case was linked to MOD-2021-122049 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 12-Mar-2021: Follow-up information On 08-May-2021: Follow up information